Shows / Community Health Media
Community Health Media
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars •…
Episodes
Community Health MediaDr. Neil Iyengar & Dr. Martin Dietrich - DESTINY-Breast09: Has HER2+ First-Line Treatment Officially Changed?
Recorded at SABCS 2025, Dr. Neil Iyengar and Dr. Martin Dietrich break down the data that may finally dethrone CLEOPATRA as the long-standing first-line…
Community Health MediaDrs. Amy Krie, Mabel Mardones, & Anne O'Dea - HER2+ Metastatic Breast Cancer: Is DB09 Leading Towards A New First-Line Standard Of Care?
Recorded live at ASCO 2025, Amy Krie, Mabel Mardones, and Anne O'Dea break down the data that could redefine first-line treatment for HER2-positive metastatic…
Community Health MediaDr. Mark Pegram & Dr. Fengting Yan - Destiny-Breast09: Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer?
Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the…
Community Health MediaDr. Bill Gradishar & Dr. Tiffany Traina - Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained
In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic…
Community Health MediaDrs. Mouabbi, O’Shaughnessy & Rimawi - 40-Month PFS? Rethinking First-Line Metastatic HER2+ Therapy with T-DXd
In this in-depth conversation, Dr. Jason Mouabbi, Dr. Joyce O’Shaughnessy, and Dr. Mothaffar Rimawi unpack the data that may redefine first-line treatment for…
Community Health MediaESMO 2025 Roundtable: Redefining HER2, ADCs & the Future of Breast Cancer Care
Recorded live at ESMO 2025 in Berlin, this expert roundtable features Drs. Adam Brufsky, VK Gadi, Ian Krop, Neil Iyengar, Paolo Tarantino, Giancarlo Moscol…
Community Health MediaDr. Neil Iyengar & Dr. Erika Hamilton - First-Line TNBC: How TRO-Breast02 & ASCENT-03 Change the Game
Triple-negative breast cancer has entered a new era. At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to…
Community Health MediaDr. Gregory Vidal and Dr. Erika Hamilton - TDXd in Early Breast Cancer: What DB-05 & DB-11 Mean for Patients
The landscape of HER2+ and HER2-low breast cancer is shifting fast — and DB-05 and DB-11 are at the center of it. In this deep-dive from ESMO 2025, Dr. Gregory…
Community Health MediaDr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC
At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative…
Community Health MediaDr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray - HER2+ Early Breast Cancer: Beyond pCR and Toward Brain Protection
Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the…
Community Health MediaDr. Neil Iyengar & Dr. Mark Robson - PARP Inhibitors in Early Breast Cancer: Who and When to Treat
From testing to treatment, the conversation around PARP inhibition in breast cancer is rapidly evolving. In this episode, Dr. Neil Iyengar and Dr. Mark Robson…
Community Health MediaDr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer
Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy. From DESTINY-Breast…
Community Health MediaDr. VK Gadi & Dr. Anne O'Dea - Advances in HER2 Positive Breast Cancer Treatment
Watch this enlightening conversation focused on the transforming power of antibody-drug conjugates (ADCs) like T-DXd (trastuzumab deruxtecan) in HER2-positive…
Community Health MediaDr. VK Gadi & Dr. Jason Mouabbi - HER2 Positive & HER2 Low Updates and Therapies
Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as…
Community Health MediaDr. Jason Mouabbi & Dr. Mothaffar Rimawi - DB09 & The Future of HER2+Care
What happens when MD Anderson’s translational firebrand Jason Mouabbi sticks a microphone in front of long-time HER2 guru Mothaffar Rimawi just days after the…
Community Health MediaDr. Jason Mouabbi & Dr. Michelina Cairo - Talking DB04 and DB06
What happens when an MD Anderson breast oncology investigator Dr. Mouabbi sits down with a high-volume community oncologist Dr. Cairo, who now treats the same…
Community Health MediaDr. VK Gadi & Dr. Fengting Yan - Navigating HER2 Low and Ultra Low Disease
When the binary “HER2-positive vs HER2-negative” model collapsed under the weight of DESTINY-Breast04 and 06, the real work began: deciding who should receive…
Community Health MediaDr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments
In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of…
Community Health MediaDr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment
In this episode of CHM Conversations, two of breast oncology’s brightest specialists — Dr. Jason Mouabbi and Dr. Paolo Tarantino — explore how trastuzumab…